TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01741441

Intervention type: PROCEDURE
Intervention: laparoscopic total fundoplication
Description: LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
Study: NCT03767452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaflex® 0.58 mg
Description: 0.25 mL injections.
Study: NCT01946386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 Aerosol, foam
Description: The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 Aerosol, foam, vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermovate® cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synalar® ointment
Study: NCT04850586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Group
Description: The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
Study: NCT02035631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Minimal diet intervention
Description: Some basic diet recommendations

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Minimal physical activity intervention
Description: Some basic recommendations on physical activity
Study: NCT00087139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study: NCT00073749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin [CMC-544]
Description: CMC-544, IV, dose escalation trial
Study: NCT05643456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: 69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking.
Study: NCT03862222

Intervention type: OTHER
Intervention: Pupillometry
Description: Participants will complete a task studying pupillary response to light

Intervention type: OTHER
Intervention: Pupillometry
Description: Participants will complete a task studying pupillary response to light
Study: NCT02184806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthotopic graft
Description: (1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heterotopic graft
Description: 1. put under the skin~2. the ovarian fragments can be put under the skin of the abdomen
Study: NCT02077803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Description: Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
Study: NCT00683813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vCRP
Description: The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
Study: NCT01293006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tablet matching suvorexant, orally, once daily, for 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tablet matching suvorexant, orally, once daily, for 4 consecutive days
Study: NCT01781741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01751672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBIRT
Description: Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT+
Description: Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
Study: NCT00869635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 Chemotherapy
Description: S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
Study: NCT01193894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Profermin
Description: Medical Food (food for special medical purposes)
Study: NCT02626364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crenolanib
Description: single-agent crenolanib at 100 mg PO TID
Study: NCT04291924

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamometry
Description: A test for maximal muscle strength and explosive power in the lower limbs

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamometry
Description: A test for maximal muscle strength and explosive power in the lower limbs
Study: NCT00525785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2.2 Gm/m\^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 200 mg/m\^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m\^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m\^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 4-6 weeks after completion of chemoradiotherapy, restaged \& surgical resection of the primary tumor and lymph nodes attempted.
Study: NCT04374201

Intervention type: OTHER
Intervention: 2 zirconia FDPs
Description: The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.

Intervention type: OTHER
Intervention: 1 zirconia FDP
Description: The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
Study: NCT04478110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.
Description: The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Session on General Health
Description: Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
Study: NCT04415619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Xenograft bone substitute (Osteo-biol)
Description: Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
Study: NCT01620697

Intervention type: PROCEDURE
Intervention: Colorectal surgery
Description: Colorectal surgery
Study: NCT01630798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI heptapeptide
Description: Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
Study: NCT02559557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in focus groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo Spanish-adapted skills training and homework assignments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Answer questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Answer questionnaires
Study: NCT02571972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol
Description: On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
Study: NCT01193894

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin
Description: Medical food (food for special medical purposes)
Study: NCT01888744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Study: NCT04537754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bleaching device
Description: activated bleaching
Study: NCT04568811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus Type-5 Vectored COVID-19 Vaccine
Description: Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)
Study: NCT01223768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-l-Carnitine
Description: 2g per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice per day
Study: NCT03947255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg given intravenously (IV)
Study: NCT01933204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Climen 21 Tablets
Description: Climen Tablets are commonly used for menopausal symptoms
Study: NCT02699853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo RRC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo ORC
Study: NCT00961662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Tagatose
Description: powder to be dissolved in water prior to dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Tagatose
Description: powder to be dissolved in water prior to dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Tagatose
Description: powder to be dissolved in water prior to dosage.
Study: NCT00556621

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin

Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine hydrochloride

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cystoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT01818986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Study: NCT00869635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
Study: NCT05080101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy Program
Description: Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy Group Program
Description: Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
Study: NCT02490267

Intervention type: OTHER
Intervention: Quality of Life questionnaire

Intervention type: OTHER
Intervention: Quality of Life questionnaire

Intervention type: OTHER
Intervention: Quality of Life questionnaire

Intervention type: OTHER
Intervention: Quality of Life questionnaire
Study: NCT04373044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given Po
Study: NCT02116426

Intervention type: BIOLOGICAL
Intervention: Blood work in the ambulance
Description: Blood sample for copeptin and troponin HS testing is taken during ambulance care.

Intervention type: BIOLOGICAL
Intervention: Blood work upon arrival in the emergency room
Description: Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.

Intervention type: BIOLOGICAL
Intervention: Blood work at 3 hours post-arrival in the emergency room
Description: Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
Study: NCT02037035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study: NCT00869635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Photodynamic therapy
Description: PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Systemic chemotherapy except S-1
Description: Variable systemic chemotherapy except S-1
Study: NCT01349205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine and sodium Benzoate 10 mg/kg IV
Description: IV, 10mg/kg, IVP, 1 time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine and Sodium Benzoate 20 mg/kg IV
Description: IV, 20 mg/kg, IVP, 1 time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 NS Saline
Description: IV, 0-10 ml, IVP, 1 time
Study: NCT02444507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium powder for injection and infusion 40 mg
Description: Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomelone Powder for Solution for Injection / Infusion 40 mg
Description: Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Study: NCT04096950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-3921 Low dose
Description: MT-3921 Low dose, intravenous, single dosing
Study: NCT04968626

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PI-LL
Description: The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
Study: NCT01990976

Intervention type: DEVICE
Intervention: MRI
Description: In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.

Intervention type: PROCEDURE
Intervention: Biopsy
Description: biopsy of the vastus lateralis muscle
Study: NCT05072054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Oral Tablet
Description: Atorvastatin 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Oral Tablet
Description: Rosuvastatin 20 mg
Study: NCT01692743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.